- What is Bicycle Therapeutics plc American Depositary Shares's Market Cap?
- Bicycle Therapeutics plc American Depositary Shares's Market Cap is $282.8M, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's Enterprise Value?
- Bicycle Therapeutics plc American Depositary Shares's Enterprise Value is -$226.5M, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's Price / Sales?
- Bicycle Therapeutics plc American Depositary Shares's Price / Sales is 4.6×, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's EV / Revenue?
- Bicycle Therapeutics plc American Depositary Shares's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's EV / EBITDA?
- Bicycle Therapeutics plc American Depositary Shares's EV / EBITDA is 1.1×, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's Revenue (TTM)?
- Bicycle Therapeutics plc American Depositary Shares's Revenue (TTM) is $61.2M, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's Net Income (TTM)?
- Bicycle Therapeutics plc American Depositary Shares's Net Income (TTM) is -$190.4M, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's EBITDA?
- Bicycle Therapeutics plc American Depositary Shares's EBITDA is -$205.0M, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's Diluted EPS (TTM)?
- Bicycle Therapeutics plc American Depositary Shares's Diluted EPS (TTM) is -2.72, based on as-reported figures from SEC (XBRL) filings.
- What is Bicycle Therapeutics plc American Depositary Shares's EBITDA Margin?
- Bicycle Therapeutics plc American Depositary Shares's EBITDA Margin is -335.0%, based on as-reported figures from SEC (XBRL) filings.